ArticleCancers2021

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.

Mélissa Prat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.